GeoVax Labs, Inc. (NASDAQ: GOVX) Releases Q2 2026 Financial Results
Key Highlights & Investor Insights
-
Quarterly Financial Performance:
GeoVax Labs, Inc. reported its results of operations for the quarter ended June 30, 2026. The company issued a press release summarizing its financial condition, which includes condensed consolidated statements of operations and balance sheet information. -
General and Administrative Expenses:
For the three-month period ended June 30, 2026, general and administrative expenses were \$1,331,564, and for the six-month period, expenses totaled \$2,700,982. This compares to \$1,542,190 and \$3,039,635 for the respective periods in 2025. The decrease was primarily due to lower investor relations consulting costs and reduced stock-based compensation expense. -
Research and Development Expense:
During the same period, research and development expenses were \$3,110,000 for the quarter and \$10,083,000 for the six months. These figures underscore the company’s continued commitment to product development and innovation. -
Operating Loss:
The loss from operations for Q2 2026 was (\$4,442,000), and for the six months ended June 30, 2026, the loss was (\$10,824,000). These losses reflect the company’s ongoing investments in research and administrative functions. -
Net Loss and Loss Per Share:
The net loss for the quarter was (\$4,427,000), with a loss per common share of (\$19.72). -
Cash Position:
GeoVax reported cash balances of approximately \$3.1 million as of June 30, 2026, unchanged from December 31, 2025. This stable cash position is crucial for ongoing operations. -
Balance Sheet Details:
– Total assets: \$6,342,000 (June 30, 2026)
– Total liabilities: \$2,517,000 (June 30, 2026)
– Stockholders’ equity: \$1,761,000 (June 30, 2026)
These details indicate the company’s financial strength and ability to fund future development. -
Shareholder Information:
The company’s common stock (par value \$0.001 per share) trades under the symbol GOVX on the Nasdaq Capital Market. -
Forward-Looking Statements:
Management cautions that forward-looking statements are based on beliefs, assumptions, and information currently available, and are subject to risks and uncertainties. Actual results may differ significantly due to various factors affecting the industry, operations, and acquisitions. -
No Pre-commencement or Soliciting Material:
The filing explicitly states that there are no written communications, soliciting materials, or pre-commencement tender offers associated with this report, which may reassure shareholders that no major corporate actions are underway at this time.
Potential Price-Sensitive Information
Investors should pay particular attention to:
- The substantial operating and net losses, which may impact future funding needs or trigger strategic changes.
- The unchanged cash position, which suggests the company has managed its cash burn rate but may need to raise additional capital if losses persist.
- Reduced administrative expenses, indicating cost control measures that may improve future profitability.
- Continued investment in research and development, supporting long-term growth and potential product commercialization.
While there are no major corporate actions disclosed in this report, investors should monitor the company’s financial trajectory, cash management, and progress in R&D, as these factors can influence share price.
Summary Table – Condensed Consolidated Statement (Q2 2026)
| Item | Q2 2026 | 6 Months Ended June 30, 2026 |
|---|---|---|
| General & Administrative Expense | \$1,331,564 | \$2,700,982 |
| Research & Development Expense | \$3,110,000 | \$10,083,000 |
| Operating Loss | (\$4,442,000) | (\$10,824,000) |
| Net Loss | (\$4,427,000) | – |
| Loss Per Share | (\$19.72) | – |
| Cash Position | \$3,100,000 (unchanged from Dec 31, 2025) | |
| Total Assets | \$6,342,000 | |
| Total Liabilities | \$2,517,000 | |
| Stockholders’ Equity | \$1,761,000 | |
Other Information
- Management Signatory: The report was signed by Mark W. Reynolds, Chief Financial Officer.
- Contact for Media: Jessica Starman ([email protected])
- Additional Details: Investors are encouraged to review the full Quarterly Report on Form 10-Q filed with the SEC for more comprehensive information.
Disclaimer
This article is provided for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should consult official SEC filings and their financial advisor before making investment decisions. The author is not responsible for actions taken based on this report.
